Furthermore, the results suggested that the activation of AMPK signaling pathway may be applied for the treatment of mutant TRPP2-related diseases, such as ADPKD, and conditions associated with TRPP2 downregulation, including tumors. This evidence concerns the gene PKD2 and autosomal dominant polycystic kidney disease.